Endocrine and clinical endpoints of exemestane as neoadjuvant therapy

Cancer Control

Volumn 9, Issue 2 SUPPL., 2002, Pages 9-15

  Miller, William R ^a   Dixon, J Michael ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROSTENEDIONE; AROMATASE INHIBITOR; CARBON 14; ESTROGEN RECEPTOR; ESTRONE; EXEMESTANE; FORMESTANE; LETROZOLE; PROGESTERONE RECEPTOR; TRITIUM;

ADULT; AGED; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; ECHOMAMMOGRAPHY; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN SYNTHESIS; FEMALE; HUMAN; HUMAN TISSUE; MAMMOGRAPHY; POSTMENOPAUSE; REVIEW; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0036236184     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480200902s02     Document Type: Review

References (23)

1. Estrogens and endocrine therapy for breast cancer
2. Analysis of cases in which oophorectomy was performed for inoperable carcinoma of the breast
3. The interconversion and aromatization of androgens by human adipose tissue
4. Aromatization of androstenedione by cultured human fibroblasts
5. Methods and results of aromatization studies in vivo
6. Oestradiol synthesis from C19 steroids by human breast cancer
7. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
8. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or Arimidex randomized group efficacy and tolerability study
9. Femara(letrozole) superior in efficacy over tamoxifen as first-line treatment in advanced breast cancer (ABC)
10. Tamoxifen vs exemestane as first-line endocrine therapy in advanced breast cancer: An EORTC randomized phase II-III trial
11. Promising activity and safety of exemestane (E) as first-line hormonal therapy (HT) in metastatic breast cancer (MBC) patients (pts): Final results of an EORTC randomized phase II trial
12. Pre-operative treatment of postmenopausal breast cancer patients with letrozole (Femara): A randomized study versus tamoxifen
13. Inactivation of aromatase in vitro by 4-hydroxy-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo
14. Aromatase within the breast
15. Antiaromatase agents: Preclinical data and neoadjuvant therapy
16. Exemestane as neoadjuvant therapy for locally advanced breast cancer: Endocrinologic and clinical endpoints
17. Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women
18. Aromatase inhibitors and enzyme stability
19. A phase II study of exemestane (EXE) in metastatic breast cancer (MBC) patients failing non steroidal aromatase inhibitors (ns-Als)
20. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
21. Pharmacology of new aromatase inhibitors
22. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multicentre multinational study
23. Lessons from the use of aromatase inhibitors in the neoadjuvant setting